Pharmacokinetics, Safety, and Tolerability of NPC‐21, an Anti‐Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo‐Controlled, First‐in‐Human Phase 1 Study-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety, and Tolerability of NPC‐21, an Anti‐Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo‐Controlled, First‐in‐Human Phase 1 Study

Published:2022-01-05 Issue:6 Volume:11 Page:707-716
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Furihata Kenichi¹,Hamada Izumi²,Niwa Takuro²,Watanabe Tatsuya²,Ezoe Sachiko³⁴

Affiliation:

1. P‐one Clinic Keikokai Medical Corporation Tokyo Japan

2. Research & Development Division Nobelpharma Co. Ltd. Tokyo Japan

3. Department of Space Infection Control, Graduate School of Medicine, Division of Health Science Osaka University Osaka Japan

4. Medical Center for Translational Research Osaka University Hospital Osaka Japan

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1065

Reference32 articles.

1. Cytomegalovirus: pathogen, paradigm, and puzzle

2. Congenital Cytomegalovirus Infection

3. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection

4. Long-term Outcomes of Congenital Cytomegalovirus Infection in Sweden and the United Kingdom

5. Clinical differentiation of infectious mononucleosis that is caused by Epstein-Barr virus or cytomegalovirus: A single-center case-control study in Japan

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of human cytomegalovirus entry into mucosal epithelial cells;Antiviral Research;2024-10

2. A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B;PLOS ONE;2023-05-16

3. Novel monoclonal antibody-based therapies: implications for the treatment and prevention of HCMV disease;Trends in Microbiology;2023-05